221 related articles for article (PubMed ID: 32161100)
1. CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells.
Rogers RF; Walton MI; Cherry DL; Collins I; Clarke PA; Garrett MD; Workman P
Cancer Res; 2020 Apr; 80(8):1735-1747. PubMed ID: 32161100
[TBL] [Abstract][Full Text] [Related]
2. Novel Amidine Derivative K1586 Sensitizes Colorectal Cancer Cells to Ionizing Radiation by Inducing Chk1 Instability.
Kim HS; Park JE; Lee WH; Kwon YB; Seu YB; Kim KS
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673980
[TBL] [Abstract][Full Text] [Related]
3. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
Booth L; Roberts J; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):786-796. PubMed ID: 30024813
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
5. A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.
Qiu Z; Fa P; Liu T; Prasad CB; Ma S; Hong Z; Chan ER; Wang H; Li Z; He K; Wang QE; Williams TM; Yan C; Sizemore ST; Narla G; Zhang J
Cancer Res; 2020 Aug; 80(16):3305-3318. PubMed ID: 32522823
[TBL] [Abstract][Full Text] [Related]
6. A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers.
Hocke S; Guo Y; Job A; Orth M; Ziesch A; Lauber K; De Toni EN; Gress TM; Herbst A; Göke B; Gallmeier E
Oncotarget; 2016 Feb; 7(6):7080-95. PubMed ID: 26755646
[TBL] [Abstract][Full Text] [Related]
7. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors.
Job A; Schmitt LM; von Wenserski L; Lankat-Buttgereit B; Gress TM; Buchholz M; Gallmeier E
Neoplasia; 2018 Nov; 20(11):1135-1143. PubMed ID: 30257222
[TBL] [Abstract][Full Text] [Related]
9. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Sen T; Tong P; Stewart CA; Cristea S; Valliani A; Shames DS; Redwood AB; Fan YH; Li L; Glisson BS; Minna JD; Sage J; Gibbons DL; Piwnica-Worms H; Heymach JV; Wang J; Byers LA
Cancer Res; 2017 Jul; 77(14):3870-3884. PubMed ID: 28490518
[TBL] [Abstract][Full Text] [Related]
10. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
[TBL] [Abstract][Full Text] [Related]
11. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
Zhang YW; Jones TL; Martin SE; Caplen NJ; Pommier Y
J Biol Chem; 2009 Jul; 284(27):18085-95. PubMed ID: 19416980
[TBL] [Abstract][Full Text] [Related]
12. The antitumor toxin CD437 is a direct inhibitor of DNA polymerase α.
Han T; Goralski M; Capota E; Padrick SB; Kim J; Xie Y; Nijhawan D
Nat Chem Biol; 2016 Jul; 12(7):511-5. PubMed ID: 27182663
[TBL] [Abstract][Full Text] [Related]
13. Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation.
Zhao X; Kim IK; Kallakury B; Chahine JJ; Iwama E; Pierobon M; Petricoin E; McCutcheon JN; Zhang YW; Umemura S; Chen V; Wang C; Giaccone G
Mol Oncol; 2021 Apr; 15(4):1130-1145. PubMed ID: 33320980
[TBL] [Abstract][Full Text] [Related]
14. Phytochemical naphtho[1,2-b] furan-4,5‑dione induced topoisomerase II-mediated DNA damage response in human non-small-cell lung cancer.
Chien CM; Yang JC; Wu PH; Wu CY; Chen GY; Wu YC; Chou CK; Tseng CH; Chen YL; Wang LF; Chiu CC
Phytomedicine; 2019 Feb; 54():109-119. PubMed ID: 30668360
[TBL] [Abstract][Full Text] [Related]
15. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
[TBL] [Abstract][Full Text] [Related]
18. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
Shibata H; Miuma S; Saldivar JC; Huebner K
Cancer Sci; 2011 Oct; 102(10):1882-8. PubMed ID: 21707865
[TBL] [Abstract][Full Text] [Related]
19. Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors.
Xiao Z; Xue J; Gu WZ; Bui M; Li G; Tao ZF; Lin NH; Sowin TJ; Zhang H
Biomarkers; 2008 Sep; 13(6):579-96. PubMed ID: 18671143
[TBL] [Abstract][Full Text] [Related]
20. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
